Review

Aging, Metabolism, and Cancer Development: from Peto’s Paradox to the Warburg Effect

Tia R. Tidwell1,2, Kjetil Søreide2,3,4, Hanne R. Hagland1,2,*

1Department of Mathematics and Natural Sciences, Centre for Organelle Research, University of Stavanger, Stavanger, Norway
2Gastrointestinal Translational Research Unit, Molecular Laboratory, Hillevåg, Stavanger University Hospital, Stavanger, Norway
3Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway
4Department of Clinical Medicine, University of Bergen, Bergen, Norway

[Received December 31, 2016; Revised April 3, 2017; Accepted June 13, 2017]

ABSTRACT: Medical advances made over the last century have increased our lifespan, but age-related diseases are a fundamental health burden worldwide. Aging is therefore a major risk factor for cardiovascular disease, cancer, diabetes, obesity, and neurodegenerative diseases, all increasing in prevalence. However, huge inter-individual variations in aging and disease risk exist, which cannot be explained by chronological age, but rather physiological age decline initiated even at young age due to lifestyle. At the heart of this lies the metabolic system and how this is regulated in each individual. Metabolic turnover of food to energy leads to accumulation of cofactors, byproducts, and certain proteins, which all influence gene expression through epigenetic regulation. How these epigenetic markers accumulate over time is now being investigated as the possible link between aging and many diseases, such as cancer. The relationship between metabolism and cancer was described as early as the late 1950s by Dr. Otto Warburg, before the identification of DNA and much earlier than our knowledge of epigenetics. However, when the stepwise gene mutation theory of cancer was presented, Warburg’s theories garnered little attention. Only in the last decade, with epigenetic discoveries, have Warburg’s data on the metabolic shift in cancers been brought back to life. The stepwise gene mutation theory fails to explain why large animals with more cells, do not have a greater cancer incidence than humans, known as Peto’s paradox. The resurgence of research into the Warburg effect has given us insight to what may explain Peto’s paradox. In this review, we discuss these connections and how age-related changes in metabolism are tightly linked to cancer development, which is further affected by lifestyle choices modulating the risk of aging and cancer through epigenetic control.

Key words: Cancer, aging, mitochondria, metabolism, Warburg effect, Peto’s paradox, epigenetics.
Aging and metabolic control

Aging is defined as a physiological decline that leads to the loss of major organ function, ultimately leading to death. The question remains as to what the cause of aging is, from an evolutionary perspective, an organism would benefit most from extended reproductive ability and lifespan. A possible answer is that aging is but a side effect of life progression and not a programmed occurrence. Supporting this is the fact that rates of aging are not fixed; for example, lower body temperatures tend to result in extended lifespan [4], possibly due to metabolic adaptations. Considering the environmental effects on rates of aging, it has become increasingly relevant in aging research to differentiate between physiological age and chronological age [5]. It is possible for two humans of identical or similar years of life, or even same genetic background as with monozygotic twins, to have very divergent states of health and lifespans [6]. The last decade of scientific research has dramatically improved our understanding of the aging process and that it is closely regulated by key metabolic proteins such as mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and insulin/insulin growth factor (IGF) [7, 8], which are associated with age-related metabolic syndrome [9] and common to those found dysregulated in cancer [10]. The long-term causative effect of aging and how this relates to increased cancer risk therefore seems to be linked through metabolic control.

Alternative to the mutational theory of cancer, the metabolic theory of cancer development is that small undetected changes in genes regulating metabolism, or mitochondrial genome mutations, can reach a threshold over time whereby it effects whole cell metabolism and confers a selective advantage for growth of that cell in an aging tissue environment [11]. Aging is linked to both the accumulation of genomic defects and that of defective proteins and organelles such as mitochondria [12, 13]. Consequently, mitochondrial defects can become prevalent in dividing stem cells by asymmetrical segregation of cell cargo. On the other hand, inheritance of “good” cargoes can enhance cell health and responsiveness, whereby more of the dysfunctional cargo is delivered to the daughter cell, which will go on to terminal differentiation, thus protecting the original stem cell [12]. Both internal and external factors may affect the growing number of dysfunctional mitochondria, speeding up the physiological aging process and cancer risk (Figure 1). However, while chronological age is immutable, physiological age depends on lifestyle choices and can be shifted to exert a beneficial effect by extending length of life and reducing disease risk.

Discoveries made in the last decade showing that most of the known oncogenes and tumor suppressor genes are metabolic regulators has rekindled Warburg’s discoveries made over a lifetime ago, highlighting the importance of metabolic control in any cell. The understanding that proteins and metabolites may be the instigators of aging and cancer development through epigenetic regulation is now a renewed research topic. This non-static mechanism of aging and cancer is gradually being accepted and helps explain why large long-lived animals with slow metabolism have a lower risk of developing cancer than humans. Of course, exposure to environmental factors are associated with increased cancer risk and can also contribute to changes in an aging system. However, these events will not be the primary focus here, since even in their complete absence, aging and cancer would occur. Therefore, this review focuses on the intrinsic events that may lead to aging and how they relate to cancer development, with a focus on the role of mitochondria and metabolism.

Mitochondrial role in cell metabolism

Mitochondria are remnants of an aerobic prokaryote that brought the selective advantage of using respiration for...
higher yield energy production to a cell dependent on rudimentary substrate fermentation. The endosymbiotic event that occurred some two billion years ago is thought to only have happened once to give rise to all advanced lifeforms known today.

Mitochondria have retained some features of a prokaryote such as double membranes and their own DNA (mtDNA), which encodes for proteins and RNAs that are mostly involved in assembling components of the electron transport chain (ETC) [14]. Mitochondrial DNA mutations, deletions, and copy number changes can result in ETC dysfunction and are believed to accumulate with aging. The increase in dysfunction of energy homeostasis with age and increase in reactive oxygen species (ROS) has been the center of the free radical theory of aging [15]. Reactive oxygen species (ROS) have also been shown to affect ETC indirectly. In *C. elegans*, repression of the *PRDX-3* gene, involved in the detoxification of mitochondrial hydrogen peroxide in the ETC, did not alter the level of ROS or life length, but instead caused mitochondrial uncoupling and decreased adenosine triphosphate (ATP) production [16], suggesting an induced compensatory response. Continuous ROS exposure has been shown to affect mitochondrial oxidative phosphorylation (OXPHOS) and ATP production by lipid peroxidation of cardiolipins [17]. Cristae invaginations caused by the unique properties of cardiolipins is essential for efficient oxidative energy production and mitochondrial function [18, 19]. Defects in the cristae formation (i.e. lipid peroxidation due to ROS) can increase the leakiness of the inner mitochondrial membrane, consequently reducing the mitochondrial ATP production [20]. Alterations of cardiolipin through years of ROS exposure may lead to gradually reduced membrane potential and consequently depolarized mitochondria with less efficient ATP production. Another consequence is an imbalance in the metabolite levels in the aging cell which could affect gene regulation and transcription epigenetically. This nuclear-mitochondrial retrograde signaling, where gene expression is regulated by metabolic substrate levels, is important to respond appropriately to metabolic stress for restoration of cell homeostasis [21, 22]. One responder to this retro-grade signaling is the evolutionarily conserved human polymerase delta (*POLD1*) gene, which is involved in multiple forms of DNA repair, and found mutated in tumors and aging [23]. The expression of this protein is further dysregulated in diabetes [24] and can be modulated by enzymes involved in metabolism such as lactate dehydrogenase and 3-phosphoglycerate [25]. This retrograde signaling from mitochondria to nuclei is triggered in normal cells by changes in metabolite levels or altered proteostasis [22, 26, 27]. Response mechanisms can include upregulation of metabolic pathways producing more metabolites, including reactive oxygen species, to act as second messengers to tune signaling pathways in the cytoplasm or directly affect gene regulation through epigenetic events. Thus, the energy status of the cell is directly linked to its replicative and reparative functions, demonstrating how metabolic substrates and enzymes regulate cell turnover [28]. In support of dysfunctional metabolism controlling cell growth, laser capture of cancer cells from colon tissue, selected by the expression of a metabolic biomarker, were deep sequenced and shown to contain mtDNA mutations from the same lineage and progenitor cell [29]. This suggests that the cancer stem cell could be traced solely by mtDNA mutations, independent of any nuclear DNA mutations. However, tumors are functionally heterogeneous and harbor subsets of cancer cells with stem-like features. Consequently, mutations of the mitochondrial genome have been tightly linked to impairment of cellular energy conversion and tissue function [30-32], and further implicated in the pathophysiology of age-associated diseases and aging itself [33, 34].

**Energy sensing mechanisms**

Life is a physical system that maintains structure and avoids decay by feeding on negative entropy through metabolism [35]. Changes in metabolites and substrate availability are reflected in the energy output of the whole cell system in the form of the ATP and adenosine monophosphate (AMP) ratio, or other reducing equivalents such as nicotinamide adenine dinucleotide (NAD*) vs NADH, which are detected by energy sensing mechanisms. Maintaining a constant ATP level within the cell is crucial, to the extent that all cells maintain a ΔG*/ATP* of approximately -56 kJ/mol [36], and any disruption of this energy balance will compromise cell function and viability [37].

Therefore, one of the central regulators of cellular and organismal metabolism in eukaryotes, and evolutionarily conserved across a multitude of species, is the AMPK [38], which acts as an integrator and mediator of several pathways and processes linking energetics to longevity. AMPK is activated by a high AMP to ATP ratio and then initiates energy producing reactions while inhibiting energy-consuming reactions as a rescue mechanism [38]. In *C. elegans*, changing the catalytic subunit of AMPK by increased expression, led to a lifespan increase of 13% [39], while a constitutively active truncated form of the protein increased life extension by 37.5 % [40]. In mammals, AMPK has a specialized function in metabolically active tissue such as the liver, adipose tissue and muscle, where it acts to integrate nutritional and hormonal signals to food intake, body weight, and
substrate homeostasis [41]. AMPK activation is further associated with inhibition of cell proliferation and is an attractive target in cancer treatment, as it shuts off metabolic cell processes needed to maintain cell proliferation [42]. A positive regulator of AMPK is the serine/threonine kinase LKB1, a known tumor suppressor, which phosphorylates the Thr172 in the activation loop of AMPK, thus inducing the downstream effects of AMPK [43]. The Peutz-Jegher cancer syndrome involves an inherited mutant form of LKB1 and is one of the most commonly known mutations in sporadic human lung cancer [44], and more recently identified in 20% of cervical carcinomas [45]. The loss of LKB1 may therefore facilitate tumor growth under energetically unfavorable conditions. As an example, AMPK activation acutely inhibits fatty acid and cholesterol synthesis through direct phosphorylation of the metabolic enzymes Acetyl-CoA carboxylase (ACC) and HMG-CoA reductase (HMGR) involved in lipid production [46], whereas a defective AMPK sensor system would allow for lipid production even under low energy stress. Increased levels of enzymes such as fatty acid synthase (FASN) involved in cell lipid production have shown to be essential for the survival of a number of cultured tumor cell lines [47-49].

Beyond the lipogenic enzymes, AMPK can acutely modulate glycolysis through phosphorylation of multiple isoforms of phosphofructo-2 kinase (PFK2), a rate-limiting enzyme of glycolysis. PFK2 phosphorylation synthesizes fructose 2,6-bisphosphate, which is a potent stimulator of glycolysis [50], thus increasing the glucose demand. This is seen in response to hypoxic conditions [51], where ATP production from mitochondria drops and AMP levels increase activating AMPK. However, under normoxic conditions, a compensatory increase in mitochondrial volume could strengthen the mitochondrial capacity to produce more ATP. This is supported by findings that AMPK can regulate mitochondrial biogenesis via the p38-PGC-1α axis, maintaining cancer cell survival under glucose-limiting normoxic conditions [52]. Getting the cell back on track energetically may be the ultimate goal of AMPK, but also makes this pathway a crucial mediator involved in both cell proliferation and longevity. Metabolic drugs, such as metformin, resveratrol, and 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside (AICAR), that directly or indirectly activate the AMPK pathway, have been associated with pro-longevity and a reduced risk of developing cancer [53-58].

Figure 1. As animals age, there is an accumulation of dysfunction. This affects the mitochondria to a great extent and a higher metabolic rate provides further amplification, reflected by the slope in this line. Once the dysfunction passes a threshold and the cell can no longer compensate, a cancerous transition may occur. The difference in resting metabolic rate (RMR) and their relative cancer development can be seen between large and small animals, with large animals having a low RMR and late or nonexistent cancer development. While RMR may not increase in larger individuals within species, metabolic stress accumulates at a faster rate and the individual can reach the dysfunctional threshold at an earlier timepoint, as exemplified here by the obese human figure having a shifted cancer risk.
Theories of carcinogenesis and Peto’s paradox

Aging and cancer involve many of the same cellular pathways in their progression, suggesting they are closely related in pathology. However, instead of following this lead, there is an ongoing pursuit to define cancers based on largely their mutational patterns. Meanwhile, the heterogenous gene expression pattern found in nearly all cancers begs the question of how critical each individual nuclear gene mutation is in the progression of the disease. Several theories exist to explain carcinogenesis, with the most prevalent being the mutation-centric theory stating that somatic nuclear mutations acquired over time eventually leads to a cancerous transition. Yet, this theory alone is unable to explain why a discrepancy exists between high cancer incidence in small, short-lived animals (i.e. few cells and less mutational events) compared to a low cancer incidence in larger, long-lived animals (i.e. many cells and more mutational events) (visualized in Fig. 1). This observation was named “Peto’s paradox” after the epidemiologist Sir Richard Peto [2]. It highlights the discrepancy that if cancers are initiated by a series of somatic mutations acquired over time and cell number, then organisms with larger body size (more cells) and longer lifespans (more cell divisions) should have a cancer risk that is orders of magnitude greater than organisms of smaller size and shorter lifespan. Thus, in theory, humans should have a higher cancer incidence than mice. However, this is not confirmed in nature, as mice have a higher risk of cancer in their relatively short lifespan (about 4 years) [59], when compared to humans. The mutation-centric theory is established on a belief that there is a linear increase in mutations during cell division as we age. This is in contradiction to data that shows that a substantial portion of somatic mutations (up to 50%) accumulate early in life before full body maturation [1] and seem to slow when stem cells convert from body building to body maintenance [60]. A further challenge with mutagenesis models is the assumption that any mutation can affect cellular fitness, which is not supported by evolutionary theory. From an evolutionary perspective, only mutations that enhance cellular fitness above others in relation to the growth environment will be advantageous [61]. Thus, both mutations and the tissue microenvironment play a role in cell growth. Early-acquired mutations may stay latent and not provide a growth advantage to cells until the tissue microenvironment changes in aging organisms, further enhancing the relationship between aging and cancer risk. This was recently shown by using a computational stochastic model integrating real data on age dependent dynamics of hematopoietic stem cell division. The model demonstrated that previously acquired mutations only became advantageous in an aging microenvironment according to non-cell-autonomous mechanisms [11]. Identification of the most prevalent mutations in cancer and their clear link to metabolic regulations [62] therefore confers that they may be providing the cells with a selective advantage for growth in a changing microenvironment.

The Warburg effect and relation to Peto’s paradox

Direct signals from mitochondria in the form of substrates, ROS, and other intermediates can affect cellular physiology via genetic and epigenetic mechanisms, and form the foundation for cancer development. The interplay between these metabolic changes, aging, and cancer development is illustrated in Figure 2. In support of the age-associated risk of cancer, tumors rarely occur following acute injury to cellular respiration and considerable time is required for non-oxidative energy metabolism (i.e. glycolysis, TCA cycle via substrate-level phosphorylation) to replace OXPHOS as the dominant energy generator of the cell. Substrate-level phosphorylation can compensate gradually for minor OXPHOS damages accumulated over time. Consequently, expansion of mtDNA mutations affecting ATP production can happen gradually [63] or by asymmetric segregation of cellular content during cell division [12]. This compensatory effect by the continued adaptation by substrate-level phosphorylation for energy production (i.e. increasing the uptake of glucose and glutamine to be broken down for ATP production) is a well-known hallmark of cancer called “the Warburg effect”. Cells that undergo a Warburg transition and switch their metabolism to glycolysis and glutaminolysis produce increased levels of substrates, such as lactate from glycolysis, and succinate, alanine, and aspartate from glutamine or amino acid fermentation [64], that can regulate gene expression epigenetically.

Otto Warburg described the change in cancer metabolism as early as the 1950s [65]. He postulated that the change to this metabolic preference was due to defective mitochondria incapable of producing enough ATP to support cell growth. However, this may not be entirely true as proliferating normal cells, such as activated lymphocytes, also revert to aerobic glycolysis upon growth activation without showing any mitochondrial dysfunction [66]. The current understanding is that rapidly proliferating cells, both normal and cancer, revert to aerobic glycolysis to support the need for new biomass when producing a daughter cell [67]. Thus, in proliferating cells, the metabolic substrate turnover rate increases to support the cell with new cell components. If one considers Warburg’s observations of increased metabolic substrate turnover in cells that are proliferating, it suggests that reduced metabolism should slow cell turnover, be cancer
preventative, and halt cell aging. Hence, in relation to Peto’s paradox, larger animals may have evolved a slower metabolic rate that is both cancer preventative and increases longevity. Indeed, the “metabolic rate hypothesis” suggests that cellular metabolic rate and subsequently, oxidative stress, decreases with increasing body size and is protective for larger animals [68]. Slower metabolic rates have been found in large, long-lived animals such as whales and elephants [59, 69-71], compared with smaller animals. A common factor among long-lived animals is that they have no natural enemies and are at reduced risk of predation or death by other external factors, thus the “need for speed” is reduced and more energy can be put into maintaining protective somatic cell maintenance [72, 73].

| Altered metabolism in aging and cancer | Mode of action | References |
|---------------------------------------|----------------|------------|
| ECM / Plasma                          | GLUCOSE        | glucose handling growth factor response |
|                                       |                | [7-10, 92, 94 138-39, 142-43] |
| Cytoplasm                             | GLUCOSE        | methylation acetylation histone modification cell cycle control |
|                                       | PYRUVA          | [101, 104, 106-08 110-14, 119-22 125-131] |
| Mitochondria                          | ACETYL-COA      | methylation prolyl hydroxylase |
|                                       | TCA Cycle       | [115-17] |
|                                       | Oxygen cycle    | AMPK histone modification |
|                                       | ATP             | [9-10, 39-46, 50-58, 92, 118, 121-124] |

Figure 2. Tumors rarely occur following acute injury to cellular respiration and considerable time is required for non-oxidative energy metabolism (i.e. glycolysis, TCA cycle via substrate-level phosphorylation) to replace oxidative phosphorylation (OXPHOS) as the dominant energy generator of the cell. As minor OXPHOS damages accumulated over time, the cell uses substrate-level phosphorylation to compensate gradually for the energy debt. This compensatory effect, by increasing the uptake of glucose and glutamine to be broken down for ATP production, is a well-known hallmark of cancer called “the Warburg effect”. Cells that undergo a Warburg transition and switch their metabolism to glycolysis and glutaminolysis produce increased levels of substrates that can have many downstream effects. Only glucose metabolism is highlighted here, with the solid arrows denoting the increased reliance on glycolysis and production of lactate, and dotted arrows denoting decreased activity in the remainder of the pathway. This translates to lowered production of acetyl-coenzyme-A (acetyl-CoA) from pyruvate, activity of the TCA cycle, and production of precursors necessary to carry out OXPHOS. Also, mutations of key TCA cycle enzymes commonly found in cancer are shown, such as isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH), as well as substrates accumulated due to their alterations. Abbreviations: ECM, extracellular matrix; IGF, insulin growth factor; SAM, s-adenosylmethionine; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine; ATP, adenosine triphosphate; AMPK, AMP-activated protein kinase.
Cellular maintenance in an aging system

The influence of metabolism on overall life span is still controversial. However, there must be an evolutionary trade-off to lower metabolic rates in larger animals to avoid cellular harm and increase life span. A possible answer is “somatic maintenance” [74], where the investment in gene repair will increase or decrease to maximize reproductive success in a changing environment. Therefore, lifespans of animals have evolved to maintain fitness and invest in somatic maintenance until reproduction is most likely to be achieved. This explains why most wild animals do not develop cancer, as they do not survive beyond reproductive age in the wild. Humans are the only species that have developed technological advances and designed their living environment to extend their lifespan far beyond reproductive age, thus exposing themselves to a variety of diseases associated with old age. This also holds true for animals kept in captivity, which live beyond their normal lifespan in the wild, and do develop cancer [75, 76].

The low cancer incidence in larger species could also relate to cell size. The difference in cell size among species has been well documented, with blood cell sizes ranging from 78 to 110 to 215 µm² in shrews, rats, humans, and whales, respectively [77, 78]. If cell size is considered when modeling cancer rates between species, then this skewed cancer risk almost disappears [68]. More importantly, in addition to the association of drop in cancer rate, larger cells exhibit a lower metabolic rate [79] and prioritize slow growth over division [80]. Furthermore, cell volume and metabolic rate scale with body mass in 13 different cell types [81], supporting the model in which metabolic rate and somatic maintenance play a crucial role in cancer development [82]. This phenomenon is only found between species and not within, as obese humans have an increased cancer risk [83] (Fig. 1). Nature’s way of combating the inherent risk of living larger is exemplified in elephants which have an increased copy number of the tumor suppressor P53 [84], leading to an improved gene maintenance system with reduced cancer risk and a longer lifespan [69]. Some exceptions to the rule do exist. For example, the naked mole rat – a small, subterranean rodent – has been found to live over 30 years, while exhibiting no documented cases of cancer [85]. As with elephants, it was recently found that the naked mole rat had fibroblasts producing a type of high-molecular-mass glycosaminoglycan, which increase extracellular matrix tension and further signals to a cell cycle checkpoint p16INK4a that inhibits cell cycle progression [86]; thus supporting the notion that the tissue microenvironment plays a major role in cell cycle regulation.

Since continual growth and aging seem to be linked, with aging perhaps being directed by this unnecessary growth [87], evidence points to energy partitioning away from biogenesis and to cell maintenance as a way to extend lifespan [88]. Cellular maintenance is carried out in various ways and exists to combat the inherent mistakes our cells accumulate as they age. The main contributors of these are gene and protein errors, and while gene instability is hallmark of cancer, we are exploring factors beyond genetics in aging and cancer. Protein homeostasis (proteostasis) is vital for quality control of the cell proteome in an aging system. Altered proteostasis can occur upon the accumulation of dysfunctional proteins due to mutations and misfolded of proteins from lack of necessary enzymes or chaperones, incorrect compartmentalization, and problems in degradation systems for the clearing of these proteins, such as autophagy-lysosomal and ubiquitin-proteasome systems [89]. Cell-stress-signaling pathways regulate the proteostasis network and prevent the toxicity associated with misfolded proteins that could aggregate in subcellular compartments and tissues. The efficiency of the proteostasis network declines with age and this failure in protein homeostasis has been proposed to underlie the basis of common age-related human disorders [90].

Autophagy is a major driver of this housekeeping role whereby unwanted, excess, or damaged cytosolic components are self-degraded by the cell through lysosomal digestion. Autophagy is one of the programmed self-degradative processes that is important for balancing sources of energy at critical times in development and in response to cellular stress [91]. Many pathways are in place to detect nutrient stress (AMPK, mTOR, FOXO), hypoxia (HIF), misfolded proteins (unfolded protein response), immune response (NF-kB, MAPK), DNA damage (P53), mitochondria stress (MMP, PINK) [92]. The selective removal of damaged mitochondria in particular has been termed mitophagy and dysregulation of this clearance is a risk factor for cancer development [93]. With decreased mitophagy, a slow accumulation of dysfunctional mitochondria may lead to accumulation of metabolic substrates causing epigenetic signaling changes and altered gene expression. In lifestyle diseases such as obesity and type 2 diabetes [94], dysfunctional mitochondria may not be cleared due to a constant excess of nutrient availability inhibiting the autophagic response mechanisms. Meanwhile, the strengthening of other metabolic pathways such as glycolysis to compensate for energy deficit provides the foundation for cancer cell transformation [95]. In mammals, one of AMPK’s many targets is the UNC-51-like kinase 1 (ULK1), which regulates the formation of the autophagosome in response to energetic stress. This regulation is thought to be an important mediator of organismal aging [96]. Most longevity-promoting interventions require an intact
autophagic machinery; furthermore, reduced autophagic activity is associated with aging while evidence suggests that enhanced autophagy promotes longevity and delays age-related phenotypes [97].

Metabolism and epigenetic changes drive aging and cancer

Deregulation and loss of homeostasis is a driver of damage and dysfunction frequently encountered in aging and cancer, affecting all functions of the cell. Normal systemic operation requires the proper flexibility and functioning of gene and protein expression to respond adequately to intracellular and extracellular signals. This flexibility is made possible by epigenetic control over how the primary DNA sequence is expressed. Besides changes in bioenergetics and creation of cellular building blocks, metabolism can affect function through control of gene expression. Much of the enzymatic maintenance of epigenetic patterns occurs through information provided by metabolic substrates and metabolites, signaling when to grow and trigger transcription based on nutrient availability. The crucial role they hold in the support of cancer growth has been proven in elegant experiments in which enucleated normal cells were fused with nuclei from tumor cells to form cybrids. These cybrid cells did not form malignant cells, whereas tumor cells infused with normal cytoplasm had their tumorigenic potential in mice reduced from 92% to 51% [98]. The important feature of their study was that the non-transformed and transformed cells all originated from a cloned progenitor cell with a common nuclear and cytoplasmic background. When the experiments were conducted, the authors did not identify the nature of the observed effects, but with experimental results from a more recent study focusing on the role of mitochondria in this situation [99], it is highly likely that substrates and intermediates of metabolism could drive this effect via epigenetic regulation. These experiments and the increasing data showing that most of the common mutations found in cancers are related to changes in metabolism [62], demonstrate that there is more than just gene mutations driving cancer and aging. Compounds directly essential to the function of epigenetic enzymes are produced during metabolism, such as S-adenosylmethionine (SAM) and alpha-ketoglutarate (α-KG), nicotinamide adenine dinucleotide (NAD) and acetyl coenzyme-A (acetyl-CoA), and uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). ATP is also vital for proper function but not rate limiting for these enzymatic reactions due to its relative abundance [100].

Methylation

SAM is produced in the cell from glycolytic intermediates shuttled to serine metabolism [101] and by addition of adenosyl to methionine from ATP. Histone methyltransferases (HMTs) and DNA methyltransferases (DNMTs) both use SAM as a methyl donor for transfer to the 5' carbon on cytosine, lysine or arginine residues of histones, respectively. α-KG is formed both in the TCA cycle from glucose-derived isocitrate by isocitrate dehydrogenase (IDH) and by transamination of glutamate [102] and is essential to the demethylation functions of lysine-specific histone demethylase I (LSD1) and JmJ-domain containing histone demethylase (JHDM) on histones, and ten-eleven translocation (TET) demethylase on DNA [103]. The effect of histone methylation depends on the specific proteins modified, and can have either repressive or enhancing effects on transcription [104], while DNA methylation results in reduced expression. There is a documented trend of methylation changes in aging, termed epigenetic drift [105], but it is difficult to tie it with specific functional implications absent of pathological symptoms. However, in a differential analysis of methylation in islet cells, genes associated with mitochondrial function and diabetes are targeted in this aging phenomenon [106]. In a study of 58 cancer cell types, DNA enhancer methylation was a strong predictor of cancer-related gene expression and of the 207 of hypomethylated/upregulated genes, two-thirds had function in metabolic processes [107]. Conversely, reduced expression of IDH and TET have been associated with decreased survival in chronic lymphocytic leukemia (CLL), but did not correlate with any measured change in global methylation [108].

Acetylation

One of the clearest links between metabolism and epigenetics is through acetyl-CoA. Acetyl-CoA plays a major role in cellular nutrient sensing is generated during oxidation of pyruvate and fatty acids in the mitochondria and from citrate in the cytosol and nucleus [109], and also serves as a substrate for lipogenesis in the cytosol. Acetyl-CoA levels directly affect the activity of histone acetyltransferases (HAT) as acetyl donors, and can act indirectly on histone deacetylation by Sirtuins due to its role in modulating NAD+/NADH by availability to the TCA cycle [110]. Histone acetylation and demethylation generally result in an open structure allowing for expression of the region, while deacetylation produces a tighter chromatin structure and reduced expression [111]. Acetyl-CoA is dynamically regulated by glucose availability in cancer cells and the ratio of acetyl-CoA: coenzyme A within the nucleus modulates global histone
acetylation levels. Reduced sirtuin (SIRT7) activity (increased acetylation) is associated with stem cell senescence and mitochondrial unfolded protein response [112]. Additionally, expression of ATG autophagy genes are tightly controlled by acetylation and thus dependent upon acetyl-coA levels and nutrient sensing by the cell with the reduction of acetyl-coA synthesis, promoting autophagy and extending lifespan in drosophila [113]. Testing in vitro and confirmation in vivo has shown histone acetylation to be controlled by glucose availability and AKT-activation of ATP-citrate lyase (ACLY), the enzyme responsible for production of acetyl-CoA from citrate [114].

**TCA Cycle Intermediates**

In the TCA cycle, metabolites such as succinate and fumarate are essential for completion of the cycle, but they may also accumulate due to altered expression of succinate dehydrogenase (SDH) and fumarate hydratase (FH) inhibiting prolyl hydroxylases (PHD) and increasing HIF levels [115]. IDH mutants produce 2-hydroxyglutarate, similar in structure to α-KG, which interferes with the normal TCA cycle and other enzymatic reactions, such as demethylation, that depend on α-KG as a substrate [116]. Mutations in IDH, FH, and SDH are common in cancer and these metabolites contribute to cancer growth and survival by reduced expression of tumor suppression genes [117].

**Chromatin modifications**

Indirectly, modifications of enzymes responsible for these epigenetic changes can increase or decrease their activity. This occurs mainly through phosphorylation and O-linked N-acetylglucosamine (O-GlcNAc) glycosylation. Modification of histones can occur by the activity of AMPK through phosphorylation of histone protein H2B, resulting in expression of genes important to the cellular energy homeostasis [118]. Changes in histones by glycosylation (formation of O-GlcNAc) are catalyzed by O-GlcNAc transferase, but little is established on the function or consequence of this histone modification type. Recently, it has been shown to have a role in H3.3-histone cell cycle regulator mediated nucleosome assembly for transcription and also cellular senescence through its regulation of chromatin dynamics [119]. The O-GlcNAc glycosylations are directly affected by nutrient availability signals and activity is reliant upon UDP-GlcNAc as a donor substrate, a product of the hexosamine biosynthesis pathway (fed by 2-5% of imported glucose), upregulated in cancer [120]. Modification of histones through phosphorylation and O-GlcNAc glycosylation are implicated in cell cycle control [121, 122] with the two exhibiting inverse relationships during different cell cycle phases. Phosphorylation of histones has been found to be a significant marker of tumor grade and mitotic index in breast cancer [123] and proliferative marker in bladder cancer [124]. Increased O-GlcNAc glycosylation is consistently found in cancer as well (breast [125, 126], prostate [127], lung [128], colorectal [128, 129], liver [130], and non-solid cancers such as chronic lymphocytic leukemia [131]) and has been correlated with increased metastatic potential. Unique modifications of histones for degradation also reveal the importance of histone turnover and homeostasis (and proteostasis) in epigenetic regulation [132]. In aging cells with DNA-damage signal activation, histone synthesis is reduced, demonstrating other ways in which histone control can affect cell homeostasis [133].

**Lifestyle modulates longevity and cancer development**

Cellular dysfunction and stress are recurring themes presented in this review for their likely role in accelerating aging and induction of cancer. This is largely due to increased metabolic activity, abnormal metabolism through diet or genetic/epigenetic modification, and inhibition of healthy cellular maintenance. These conditions are all capable of improvement through lifestyles changes.

In the developed world, food sources are constantly available and reduction of metabolic activity by prolonged fasting is rarely achieved. We no longer experience seasonal or periodic fluctuations in nutrient availability like our ancestors, but still have a vital and complex nutrient sensing system that can be severely affected by our modern diets. Reducing this excess consumed energy should result in a longer and healthier lifespan by decreasing metabolic activity and energy partitioning, ROS, and epigenetic-affecting metabolites. Calorie restriction was one of the first diets to show a direct relationship between metabolism and lifespan extension [134], and continues to be lauded as the best option for life extension and health [135]. The consumption of reduced calories, but not below nutritional levels, has been shown to reduce resting metabolic rate [136], and depends on mitochondrial function for its beneficial outcomes [137]. Calorie restriction and associated dietary restriction seem to exert their effects specifically through mTOR, AMPK, and glucose handling (IGF/insulin) pathways [138, 139] with outcomes such as lifespan extension, reduced inflammation and cancer. Taking the restriction further to a pure ketogenic diet has been shown in mice to reduce metabolic activity and increase uncoupling protein 2 and the ketone, beta-hydroxybutyrate [140]. Ketone bodies are important compounds in the body’s response to restricted nutrients; as a precursor to acetyl-CoA it serves
as an energy source and donor for epigenetic modifications [141]. For more information on lifestyle modulations such as calorie and dietary restrictions, micro/macronutrients, and meal timing, Fontana et al. [142] provides a complete review. Diet is not the only negative modern lifestyle factor we have altered, however; sleep and circadian alignment are adjusted to fit societal norms and they also have large effects on metabolism and cell recovery. Most research in this area is performed on shift workers or through short-term sleep deprivation. While only shift work results in circadian misalignment, even a single night of sleep restriction can mimic its effects and both have been related to increased insulin resistance [143, 144].

Calorie and dietary restrictions in combination with regular sleeping patterns can lead to a more normal metabolism primarily through direct influx of nutrients and also regulation of cellular processes through healthy maintenance. The mild stress on mitochondria by preserving short periods of low-nutrients can induce retrograde stress responses and actually enhance cellular function by retaining the activity of autophagic processes. As mentioned before in relation to obesity and diabetes II, such activation of unfolded protein response and IGF has been induced by redox stress to mitochondria (mitohormesis) in muscle of Drosophila, resulting in increased mitophagy and lifespan [94]. These changes in lifestyle have persistent effects in major metabolic pathways, ROS, mitochondrial turnover, immune regulation, epigenetic control, and DNA repair; related to both aging and cancer.

**Concluding remarks**

Further investigation into the differentiating genetic or metabolic factors between species is a key to understanding the source of neoplasms and the mechanisms nature has adapted to fight them. With the explanations given here and even the outliers of Peto’s paradox, a need to explain cancer formation using only the multi-stage mutational model lessens. The refitting of the model with respect to cell size and volume, differential tissue behavior, and the presence of long-living organisms with no cancer at all could have a unifying relationship within cell metabolism. Larger cells, less proliferating tissues, and long-living organisms all have slow metabolism and consequently slower cell growth. Upon analysis, carcinogenesis may be driven by a forced change in metabolism that is not tolerated by an organism or tissue and its adapted mechanisms.

To further expand the knowledge of how these factors are regulating aging and cancer development, there is a need to share and compare the accumulated evidence that underlies these mechanisms. The close relationship between aging, cancer, and metabolism across species can be addressed using accessible databases depositing published data. The era of computer science and technology which in many aspects seem to be outpacing our evolutionary adaptation to lifestyle changes, could very well be the technology that will help solve this puzzle. The ability to completely prevent aging and cancer is doubtful, but as said by Stauch et al., “Aging is not necessarily pathogenic, and in healthy aging, organs, cells and subcellular organelles can respond to gradual age-associated stress” [145]. Armed with knowledge that our diet and behavior matter on a molecular level, we can make healthy lifestyle choices and allow our bodies to combat this gradual stress, while attempting to alleviate the modern prevalence of aging pathology and tumorigenesis.

**References**

[1] Vijg J, Busuttil RA, Bahar R, Dolle ME (2005). Aging and genome maintenance. Ann N Y Acad Sci, 1055: 35-47
[2] Peto R (1977) Epidemiology, Multistage Models, and Short-term Mutagenicity Tests. In *The Origins of Human Cancer* pp. 1403-1428, NY: Cold Spring Harbor Conferences on Cell Proliferation
[3] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136: E359-E386
[4] Keil G, Cummings E, de Magalhaes JP (2015). Being cool: how body temperature influences ageing and longevity. Biogerontology, 16: 383-397
[5] Horvath S (2013). DNA methylation age of human tissues and cell types. Genome Biol, 14
[6] Bell JT, Spector TD (2011). A twin approach to unraveling epigenetics. Trends Genet, 27: 116-125
[7] Johnson SC, Rabinovitch PS, Kaebelerin M (2013). mTOR is a key modulator of ageing and age-related disease. Nature, 493: 338-345
[8] Kennedy Brian K, Lamming Dudley W (2016). The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab, 23: 990-1003
[9] Bonomini F, Rodella LF, Rezzani R (2015). Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis, 6: 109-120
[10] DeBerardinis RJ, Chandel NS (2016). Fundamentals of cancer metabolism. Sci Adv, 2: e1600200
[11] Rozhkov AI, Salstrom JL, DeGregori J (2014). Stochastic modeling indicates that aging and somatic evolution in the hematopoietic system are driven by non-cell-autonomous processes. Aging (Albany NY), 6: 1033-1048
[12] Moore DL, Jessberger S, Henderson KA, Gottschling DE, Pelletier L, Yamashita YM, et al. (2016). Creating Age Asymmetry: Consequences of Inheriting
Damaged Goods in Mammalian Cells. Trends Cell Biol, 0: 723-728

[13] Kauppila TES, Kauppila JHK, Larsson N-G (2016). Mammalian Mitochondria and Aging: An Update. Cell Metab, 25

[14] Anderson S, Bankier AT, Barrell BG, de Bruiijn MH, Coulson AR, Drouin J, et al. (1981). Sequence and organization of the human mitochondrial genome. Nature, 290: 457-465

[15] Harman D (2009). Origin and evolution of the free radical theory of aging: a brief personal history, 1954-2009. Biogerontology, 10: 773-781

[16] Ranjan M, Gruber J, Ng LF, Halliwell B (2013). Repression of the mitochondrial peroxiredoxin antioxidant system does not shorten life span but causes reduced fitness in Caenorhabditis elegans. Free Radic Biol Med, 63: 381-389

[17] Paradis G, Petrosillo G, Pistolese M, Ruggiero FM (2002). Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene, 286: 135-141

[18] Hoch FL (1992). Cardiolipins and biomembrane function. Biochim Biophys Acta Rev Biomembr, 1113: 71-133

[19] Fry M, Green DE (1981). Cardiolipin Requirement for Electron Transfer in Complex I and I1 of the Mitochondrial Respiratory Chain*. J Biol Chem, 256: 1874-1880

[20] Claypool SM (2009). Cardiolipin, a critical determinant of mitochondrial carrier protein assembly and function. Biochim Biophys Acta, 1788: 2059-2068

[21] Nunnari J, Suomalainen A (2012). Mitochondria: in sickness and in health. Cell, 148: 1145-1159

[22] Kotiadis VN, Duchen MR, Osellame LD (2014). Mitochondrial quality control and communications with the nucleus are important in maintaining mitochondrial function and cell health. Biochim Biophys Acta, 1840: 1254-1265

[23] Nicolas E, Golemis EA, Arora S (2016). POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. Gene, 590: 128-141

[24] Zhou H, Saito S, Piao G, Liu ZP, Wang J, Horimoto K, et al. (2011). Network screening of Goto-Kakizaki rat liver microarray data during diabetic progression. BMC Syst Biol, 5 Suppl 1: S16

[25] Popanda O, Fox G, Thielmann HW (1998). Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta, 1397: 102-117

[26] Chandel NS (2014). Mitochondria as signaling organelles. BMC Biol, 12: 34

[27] Whelan SP, Zuckerbraun BS (2013). Mitochondrial signaling: forwards, backwards, and in between. Oxid Med Cell Longev, 2013: 351613

[28] Konieczna A, Szczepanska A, Sawiuk K, Wegrzyn G, Lyzen R (2015). Effects of partial silencing of genes coding for enzymes involved in glycolysis and tricarboxylic acid cycle on the entrance of human fibroblasts to the S phase. BMC Cell Biol, 16: 16

[29] Walther V, Alison MR (2016). Cell lineage tracing in human epithelial tissues using mitochondrial DNA mutations as clonal markers. Wiley Interdiscip Rev Dev Biol, 5: 103-117

[30] Chinnery PF, Dimauro PS, Shanske S, Schon PEA, Zeviani M, Mariotti C, et al. (2004). Risk of developing a mitochondrial DNA deletion disorder. Lancet, 364: 592-596

[31] Chinnery PF (2015). Mitochondrial disease in adults: what’s old and what’s new? EMBO Mol Med, 7: 1503-1512

[32] Lightowlers RN, Taylor RW, Turnbull DM (2015). Mutations causing mitochondrial disease: What is new and what challenges remain? Science, 349: 1494-1499

[33] Larsson NG (2010). Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem, 79: 683-706

[34] Payne BAI, Chinnery PF (2015). Mitochondrial dysfunction in aging: Much progress but many unresolved questions. Biochim Biophys Acta, Bioenergetics, 1847: 1347-1353

[35] Schrodinger E (1992) What is life?: With "mind and matter" and autobiographical sketches., Cambridge University Press, Cambridge, UK

[36] Veech RL, Chance B, Kashiwaya Y, Lardy Ha, Cahill GF (2001). Ketone bodies, Potential Therapeutic Uses. IUBMB Life, 51: 241-247

[37] Veech RL, Kashiwaya Y, Gates DN, King MT, Clarke K (2002). The energetics of ion distribution: the origin of the resting electric potential of cells. IUBMB Life, 54; 241-252

[38] Mihaylova MM, Shaw RJ (2013). The AMP-activated protein kinase (AMPK) signaling pathway coordinates cell growth, autophagy, & metabolism. Nat Cell Biol, 13: 1016-1023

[39] Apfeld J, O'Connor G, McDonagh T, DiStefano PS, Curtis R (2004). The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev, 18: 3004-3009

[40] Mair W, Morantte I, Rodrigues AP, Manning G, Montminy M, Shaw RJ, et al. (2011). Lifespan extension induced by AMPK and calcineurin is mediated by CRTCL-1 and CREB. Nature, 470: 404-408

[41] Kahn BB, Alquier T, Carling D, Hardie DG (2005). AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 1: 15-25

[42] Shackelford DB, Shaw RJ (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer, 9: 563-575

[43] Hawley SA, Bodeau J, Reid JL, Mustard KJ, Udd L, Makela TP, et al. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol, 2: 28

[44] Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. (2002). Inactivation of
LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res, 62: 3659-3662

Wingo SN, Gallardo TD, Akbay EA, Liang M-C, Contreras CM, Boren T, et al. (2009). Somatic LKB1 Mutations Promote Cervical Cancer Progression. PLoS One, 4: e5137

Carling D, Zammit VA, Hardie DG (1987). A common cyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett, 223: 217-222

Zhan Y, Ginanni N, Tota MR, Wu M, Bays NW, Richon VM, et al. (2008). Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin Cancer Res, 14: 5735-5742

Chajès V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006). Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res, 66: 5287-5294

Brusselmans K, Schrijver ED (2005). RNA Interference-Mediated Silencing of the Acetyl-CoA-Carboxylase-α Gene Induces Growth Inhibition and Apoptosis of Prostate Cancer Cells. Cancer Res: 6719-6726

Almeida A, Moncada S, Bolaños JP (2004). Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol, 6: 45-51

Sancho P, Barneda D, Heesch C (2016). Hallmarks of cancer stem cell metabolism. Br J Cancer, 114: 1305-1312

Chaube B, Malvi P, Singh SV, Mohammad N, Viollet B, Bhat MK (2015). AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1α-mediated mitochondrial biogenesis. Cell Death Discov, 1: 15063

Anisimov VN (2015). Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget, 6: 39398-39407

Azuolay L, Dell’Amiello S, Gagnon B, Pollak M, Suissa S (2011). Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev, 20: 337-344

Bansal M, Siegel E, Govindarajan R (2011). The effect of metformin on overall survival of patients with colorectal cancer treated with chemotherapy. J Clin Oncol, 29

Bridges Hannah R, Jones Andrew JY, Pollak Michael N, Hirst J (2014). Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochim J, 462: 475-487

Sui X, Xu Y, Yang J, Fang Y, Lou H, Han W, et al. (2014). Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS One, 9: e97781

Bonkowski MS, Sinclair DA (2016). Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol, 17: 679-690

Dang CV (2012). Links between metabolism and cancer. Genes Dev, 26: 877-890

Bowie MB, McKnight KD, Kent DG, McCaffrey L, Hoodless PA, Eaves CJ, et al. (2006). Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J Clin Invest, 116: 2808-2816

Cairns J (1975). Mutation selection and the natural history of cancer. Nature, 255: 197-200

Pavlova NN, Thompson CB (2016). The Emerging Hallmarks of Cancer Metabolism. Cell Metab, 23: 27-47

Elson JL, Samuels DC, Turnbull DM, Chinnery PF (2001). Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age. Am J Hum Genet, 68: 802-806

Seyfried TN, Flores RE, Poff AM, D’Agostino DP (2014). Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 35: 515-527

Warburg O (1956). On the origin of cancer cells. Science, 123: 412-421

Altman BI, Dang CV (2012). Normal and cancer cell metabolism: lymphocytes and lymphoma. FEBS J, 279: 2598-2609

Vander Heiden MG, Cantley LC, Thompson CB (2009). Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science, 324

Caulin AF, Maley CC (2011). Peto’s Paradox: Evolution’s prescription for cancer prevention. Trends Ecol Evol, 26: 175-182

Speakman JR (2005). Body size, energy metabolism and lifespan. J Exp Biol, 208: 1717-1730

Martin AP, Palumbi SR (1993). Body size, metabolic rate, generation time, and the molecular clock. Proc Natl Acad Sci U S A, 90: 4087-4091

Caulin AF, Graham TA, Wang L-S, Maley CC (2015). Solutions to Peto’s paradox revealed by mathematical modelling and cross-species cancer gene analysis. Philos Trans R Soc Lond B Biol Sci, 370: 20140222-20140222

Glazier DS (2015). Is metabolic rate a universal “pacemaker” for biological processes? Biol Rev Camb Philos Soc, 90: 377-407

Glazier DS (2010). A unifying explanation for diverse metabolic scaling in animals and plants. Biol Rev Camb Philos Soc, 85: 111-138

Rozhok AI, DeGregori J (2016). The Evolution of Lifespan and Age-Dependent Cancer Risk. Trends Cancer, 2: 552-560

Martineau D, Lemberger K, Dallaire A, Labelle P, Lipscomb TP, Michel P, et al. (2002). Cancer in wildlife, a case study: beluga from the St. Lawrence estuary, Quebec, Canada. Environ Health Perspect, 110: 285-292

Lair S, Mehren KG, Barker IK, Williams ES (2002). Epidemiology of neoplasia in captive black-footed ferrets (Mustela nigripes), 1986-1996. J Zoo Wildl Med, 33: 204-213

Gregory TR (2017) Animal Genome Size Database. Maciak S, Michalak P (2015). Cell size and cancer: A...
new solution to Peto's paradox? Evol Appl, 8: 2-8

White CR, Kearney MR (2013). Determinants of inter-specific variation in basal metabolic rate. J Comp Physiol B, 183: 1-26

[80] Kooijman SALM (2009) *Dynamic Energy Budget theory for metabolic organisation*, Cambridge University Press, Great Britain

[81] Jayasundara N, Kozal JS, Arnold MC, Chan SSL, Di Giulio RT (2015). High-throughput tissue bioenergetics analysis reveals identical metabolic allometric scaling for teleost hearts and whole organisms. PLoS One, 10: e0137710

[82] Dang CV (2015). A metabolic perspective of Peto’s paradox and the integrated stress response. Mol Cell, 40: 12

[83] Calle EE, Thun MJ (2004). Obesity and cancer. Oncogene, 23: 6365-6378

[84] Abeglen LM, Caulin AF, Chan A, Lee K, Robinson R, Campbell MS, et al. (2015). Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans. JAMA, 67: 223-230

[85] Kim EB, Fang X, Fushman AA, Huang Z, Lobanov AV, Han L, et al. (2011). Genome sequencing reveals insights into physiology and longevity of the naked mole rat. Nature, 479: 223-227

[86] Tian X, Azpurua J, Hine C, Vaidya A, Vlahakis- M, Ablaeva J, et al. (2014). High molecular weight hyaluronan mediates the cancer resistance of the naked mole-rat. Nature, 499: 346-349

[87] Blagosklonny MV, Hall MN (2009). Growth and aging: a common molecular mechanism. Aging (Milano), 1: 357-362

[88] Hou C, Bolt K, Bergman A (2011). A General Life History Theory for Effects of Caloric Restriction on Health Maintenance. BMC Syst Biol, 5: 78

[89] Triplett JC, Tramutola A, Swomley A, Kirk J, Grimes K, Lewis K, et al. (2015). Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity. Biochim Biophys Acta, Mol Basis Dis, 1852: 2213-2224

[90] Morimoto RI, Cuervo AM (2014). Proteostasis and the aging proteome in health and disease. J Gerontol A Biol Sci Med Sci, 69: S33-38

[91] Glick D, Barth S, Macleod KF (2010). Autophagy: cellular and molecular mechanisms. J Pathol, 221: 3-12

[92] Kroemer G, Marino G, Levine B (2010). Autophagy and the integrated stress response. Mol Cell, 40: 280-293

[93] Bernardini JP, Lazarou M, Dewson G (2017). Parkin and mitophagy in cancer. Oncogene, 36: 1315-1327

[94] Owusu-Ansah E, Song L, Perrinn N, Alic N, Hoddinott MP, Vinti G, et al. (2013). Muscle mitohormesis promotes longevity via systemic repression of insulin signaling. Cell, 155: 699-712

[95] Ward PS, Thompson CB (2012). Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell, 21: 297-308

[96] Ulgherait M, Rana A, Rera M, Granier J, Walker DW (2014). AMPK modulates tissue and organismal aging in a non-cell-autonomous manner. Cell Rep, 8: 1767-1780

[97] Rubinsztein DC, Marino G, Kroemer G (2011). Autophagy and aging. Cell, 146: 682-695

[98] Israel BA, Schaeffer WI (1987). Cytoplasmic suppression of malignancy. In Vitro Cell Dev Biol, 23: 627-632

[99] Kaipparettu BA, Ma Y, Park JH, Lee T-I, Zhang Y, Yotnda P, et al. (2013). Crosstalk from Non-Cancerous Mitochondria Can Inhibit Tumor Properties of Metastatic Cells by Suppressing Oncogenic Pathways. PLoS One, 8: 1-9

[100] Locasale JW, Cantley LC (2011). Metabolic flux and the regulation of mammalian cell growth. Cell Metab, 14: 443-451

[101] Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G (2014). Serine and glycine metabolism in cancer. Trends Biochem Sci, 39: 191-198

[102] Yun J, Johnson JL, Hanigan CL, Locasale JW (2012). Interactions between epigenetics and metabolism in cancers. Front Oncol, 2: 163

[103] Lu C, Thompson CB (2012). Metabolic regulation of epigenetics. Cell Metab, 16: 9-17

[104] Zhang Y, Reinberg D (2001). Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev, 15: 2343-2360

[105] Zampieri M, Ciccarone F, Calabrese F, Franceschi C, Burkle A, Caiapa P (2015). Reconfiguration of DNA methylation in aging. Mech Ageing Dev, 151: 60-70

[106] Bacos K, Gillberg L, Volkov P, Olsson AH, Hansen T, Pedersen O, et al. (2016). Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes. Nat Commun, 7: 11089

[107] Aran D, Sabato S, Hellman A (2013). DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol, 14: R21

[108] Van Damme M, Cromptot E, Meuleman N, Maerevoet M, Mineur P, Bron D, et al. (2016). Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance. Clin Epigenetics, 8: 132

[109] Choudhary C, Weintert BT, Nishida Y, Verdin E, Mann M (2014). The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol, 15: 536-550

[110] Webster BR, Scott I, Traba J, Han K, Sack MN (2014). Regulation of autophagy and mitophagy by nutrient availability and acetylation. Biochim Biophys Acta, 1841: 525-534

[111] Kaelin WG, McKnight SL (2013). Influence of metabolic changes on the regulation of mammalian cell growth. Trends Biochem Sci, 39: 191-198

[112] Mohrin M, Shin J, Liu Y, Brown K, Luo H, Xi Y, et al. (2015). Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates...
GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res, 70: 6344-6351

Tidwell T.R., et al

Aging, metabolism and cancer development

Vosseller K, Reginato MJ (2012). Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem, 287: 11070-11081

Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. (2011). O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta, Mol Basis Dis, 1812: 514-519

Yehezkel G, Cohen L, Kligler A, Manor E, Khalalai I (2012). O-linked beta-N-acetylglucosaminylolation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-beta-D-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem, 287: 28755-28769

Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. (2012). O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol, 29: 985-993

Shi Y, Tomic J, Wen F, ShaHa S, Bahlo A, Harrison R, et al. (2010). Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia, 24: 1588-1598

Biterge B, Richter F, Mittler G, Schneider R (2014). Methylation of histone H4 at aspartate 24 by protein L-isoaaspartate O-methyltransferase (PCMT1) links histone modifications with protein homeostasis. Sci Rep, 4: 6674

O'Sullivan R, Kubiece S, Schreiber SL, Karlseder J (2010). Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol, 17: 1218-1225

Goodrick CL, Ingram DK, Reynolds MA, Freeman JR, Cider NL (1983). Differential effects of intermittent feeding and voluntary exercise on body weight and lifespan in adult rats. J Gerontol, 38: 36-45

Meynet O, Ricci J-E (2014). Caloric restriction and cancer: molecular mechanisms and clinical implications. Trends Mol Med, 20: 419-427

Ravussin E, Redman LM, Rochon J, Das SK, Fontana L, Kraus WE, et al. (2015). A 2-year randomized controlled trial of human caloric restriction: Feasibility and effects on predictors of health span and longevity. J Gerontol A Biol Sci Med Sci, 70: 1097-1104

Mitchell SJ, Madrigal-Mature J, Scheibye-Knudsen M, Fang E, Aon M, Gonzalez-Reyes JA, et al. (2016). Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice. Cell Metab, 23: 1093-1112

Solon-Biet Samantha M, McMahon Aising C, Ballard JW, William O, Ruohonkeli, W, Wu Lindsay E, Cogger Victoria C, et al. (2014). The Ratio of Macronutrients, Not Caloric Intake, Dictates Cardiometabolic Health, Aging, and Longevity in Ad Libitum-Fed Mice. Cell Metab, 19: 418-430

Brandhorst S, Choi YI, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. (2015). A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab, 22: 86-99

Douris N, Melman T, Pecherer JM, Pissios P, Flier JS,
Cantley LC, et al. (2015). Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet. Biochim Biophys Acta, Mol Basis Dis, 1852: 2056-2065

[141] Newman JC, Verdin E (2014). Ketone bodies as signaling metabolites. Trends Endocrinol Metab, 25: 42-52

[142] Fontana L, Partridge L (2015). Promoting health and longevity through diet: From model organisms to humans. Cell, 161: 106-118

[143] Donga E, Van Dijk M, Van Dijk JG, Biermasz NR, Lammers GJ, Van Kralingen KW, et al. (2010). A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab, 95: 2963-2968

[144] Morris CJ, Purvis TE, Mistretta J, Scheer FAJL (2016). Effects of the internal circadian system and circadian misalignment on glucose tolerance in chronic shift workers. J Clin Endocrinol Metab, 101: 1066-1074

[145] Stauch KL, Purnell PR, Fox HS (2014). Aging synaptic mitochondria exhibit dynamic proteomic changes while maintaining bioenergetic function. Aging (Milano), 6: 320-334